Radiation risk of central nervous system tumors in the Life Span Study of atomic bomb survivors, 1958-2009.
Adult
Atomic Bomb Survivors
/ statistics & numerical data
Central Nervous System Neoplasms
/ epidemiology
Cohort Studies
Dose-Response Relationship, Radiation
Female
Glioma
/ epidemiology
Humans
Japan
/ epidemiology
Longevity
Male
Meningioma
/ epidemiology
Middle Aged
Neoplasms, Radiation-Induced
/ epidemiology
Neurilemmoma
/ epidemiology
Radiation Exposure
/ adverse effects
Registries
Risk Assessment
Atomic bombs
CNS tumor
Cohort studies
Etiology
Risk assessment
Journal
European journal of epidemiology
ISSN: 1573-7284
Titre abrégé: Eur J Epidemiol
Pays: Netherlands
ID NLM: 8508062
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
30
07
2019
accepted:
28
12
2019
pubmed:
27
1
2020
medline:
26
9
2020
entrez:
27
1
2020
Statut:
ppublish
Résumé
Radiation exposure is among the few factors known to be associated with risk of central nervous system (CNS) tumors. However, the patterns of radiation risk by histological type, sex or age are unclear. We evaluated radiation risks of first primary glioma, meningioma, schwannoma, and other or not otherwise specified (other/NOS) tumors in the Life Span Study cohort of atomic bomb survivors. Cases diagnosed between 1958 and 2009 were ascertained through population-based cancer registries in Hiroshima and Nagasaki. To estimate excess relative risk per Gy (ERR/Gy), we fit rate models using Poisson regression methods. There were 285 CNS tumors (67 gliomas, 107 meningiomas, 49 schwannomas, and 64 other/NOS tumors) among 105,444 individuals with radiation dose estimates to the brain contributing 3.1 million person-years of observation. Based on a simple linear model without effect modification, ERR/Gy was 1.67 (95% confidence interval, CI: 0.12 to 5.26) for glioma, 1.82 (95% CI: 0.51 to 4.30) for meningioma, 1.45 (95% CI: - 0.01 to 4.97) for schwannoma, and 1.40 (95% CI: 0.61 to 2.57) for all CNS tumors as a group. For each tumor type, the dose-response was consistent with linearity and appeared to be stronger among males than among females, particularly for meningioma (P = 0.045). There was also evidence that the ERR/Gy for schwannoma decreased with attained age (P = 0.002). More than 60 years after the bombings, radiation risks for CNS tumors continue to be elevated. Further follow-up is necessary to characterize the lifetime risks of specific CNS tumors following radiation exposure.
Identifiants
pubmed: 31982981
doi: 10.1007/s10654-019-00599-y
pii: 10.1007/s10654-019-00599-y
pmc: PMC7329623
mid: NIHMS1552277
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
591-600Subventions
Organisme : NCI NIH HHS
ID : HHSN261201400009C
Pays : United States
Références
Radiat Res. 2007 Jul;168(1):1-64
pubmed: 17722996
Radiat Res. 2016 May;185(5):473-84
pubmed: 27128740
Lancet Haematol. 2018 Aug;5(8):e346-e358
pubmed: 30026010
Oncogene. 2011 May 19;30(20):2333-44
pubmed: 21242963
Radiat Res. 2018 Feb;189(2):128-135
pubmed: 29206598
Neuro Oncol. 2008 Feb;10(1):73-8
pubmed: 18079359
J Radiol Prot. 2016 Dec;36(4):953-974
pubmed: 27893452
Radiat Res. 1990 Sep;123(3):275-84
pubmed: 2217725
Lancet. 2012 Nov 17;380(9855):1735-6; author reply 1736-7
pubmed: 23158241
J Neurooncol. 2002 Oct;60(1):61-9
pubmed: 12416547
Neuro Oncol. 2012 Nov;14(11):1316-24
pubmed: 22952197
J Clin Oncol. 2010 Dec 20;28(36):5287-93
pubmed: 21079138
Presse Med. 2018 Nov - Dec;47(11-12 Pt 2):e187-e200
pubmed: 30449638
World Neurosurg. 2014 Nov;82(5):906-11
pubmed: 24928363
Health Phys. 2001 May;80(5):491-6
pubmed: 11316080
Ann ICRP. 2015 Jun;44(1 Suppl):236-48
pubmed: 25816281
Cancer. 2004 Oct 1;101(7):1644-54
pubmed: 15378499
Int J Cancer. 1998 Oct 29;78(3):269-75
pubmed: 9766556
Br J Cancer. 2016 Feb 16;114(4):388-94
pubmed: 26882064
Health Phys. 2017 Jan;112(1):56-97
pubmed: 27906788
Br J Cancer. 2016 Dec 6;115(12):1445-1450
pubmed: 27832665
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Health Phys. 2003 Oct;85(4):404-8
pubmed: 13678280
Int J Radiat Biol. 2019 Jul;95(7):879-891
pubmed: 30676179
Radiat Res. 2017 May;187(5):513-537
pubmed: 28319463
Stat Med. 2007 Jul 10;26(15):3018-45
pubmed: 17177166
Radiat Res. 2006 Jul;166(1 Pt 2):219-54
pubmed: 16808610
Lancet. 2012 Nov 17;380(9855):1736; author reply 1736-7
pubmed: 23158245
J Natl Cancer Inst. 2019 Mar 1;111(3):256-263
pubmed: 30020493
Radiat Res. 1993 May;134(2):134-42
pubmed: 8488248
J Neurooncol. 2010 Sep;99(3):307-14
pubmed: 20821343
Radiat Res. 2010 Jul;174(1):72-82
pubmed: 20681801
J Natl Cancer Inst. 2006 Nov 1;98(21):1528-37
pubmed: 17077355
Radiat Res. 2005 Apr;163(4):424-32
pubmed: 15799699
Lancet. 2012 Aug 4;380(9840):499-505
pubmed: 22681860
Eur J Epidemiol. 2017 Dec;32(12):1055-1063
pubmed: 29204903
Acta Oncol. 2006;45(4):438-48
pubmed: 16760180
Lancet. 2012 Nov 17;380(9855):1735; author reply 1736-7
pubmed: 23158243
J Natl Cancer Inst. 2002 Oct 16;94(20):1555-63
pubmed: 12381708
Radiat Res. 1998 Sep;150(3):357-64
pubmed: 9728664
BMJ. 2013 May 21;346:f2360
pubmed: 23694687